Publication Date:
1991-06-21
Description:
Infection by human immunodeficiency virus type 1 (HIV-1) is associated with cellular activation and expression of the interleukin-2 (IL-2) receptor. A genetically engineered fusion toxin, DAB486 IL-2, that contains the enzymatic site and translocation domain of diphtheria toxin and the receptor binding domain of IL-2 specifically kills cells that express high-affinity IL-2 receptors. This toxin selectively eliminated the HIV-1-infected cells from mixed cultures of infected and uninfected cells and inhibited production of viral proteins and infectious virus. Thus, cellular activation antigens present a target for early antiviral intervention.〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Finberg, R W -- Wahl, S M -- Allen, J B -- Soman, G -- Strom, T B -- Murphy, J R -- Nichols, J C -- New York, N.Y. -- Science. 1991 Jun 21;252(5013):1703-5.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉Laboratory of Infectious Diseases, Dana-Farber Cancer Institute, Boston, MA.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/1904628" target="_blank"〉PubMed〈/a〉
Keywords:
Cell Survival
;
Diphtheria Toxin/*administration & dosage/genetics
;
Gene Products, env/metabolism
;
Gene Products, gag/metabolism
;
HIV Core Protein p24
;
HIV Envelope Protein gp160
;
HIV Infections/*therapy
;
HIV-1/metabolism
;
Humans
;
In Vitro Techniques
;
Interleukin-2/genetics/metabolism
;
Protein Precursors/metabolism
;
Receptors, Interleukin-2/*physiology
;
Recombinant Fusion Proteins/toxicity
;
T-Lymphocytes/cytology/*microbiology
;
Viral Core Proteins/metabolism
Print ISSN:
0036-8075
Electronic ISSN:
1095-9203
Topics:
Biology
,
Chemistry and Pharmacology
,
Computer Science
,
Medicine
,
Natural Sciences in General
,
Physics
